These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 25192588)
1. The prognostic value of lymph node status among breast cancer subtypes. Liao GS; Chou YC; Hsu HM; Dai MS; Yu JC Am J Surg; 2015 Apr; 209(4):717-24. PubMed ID: 25192588 [TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer]. Liu ZF; Chen C; Yao XL; Sun SR Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638 [TBL] [Abstract][Full Text] [Related]
3. [Survival analysis for different molecular subtypes of breast cancers after treatment]. He YJ; Li JF; Wang TF; Xie YT; Fan ZQ; Wang LZ; Ying M; Ouyang T Zhonghua Yi Xue Za Zhi; 2013 Dec; 93(46):3663-6. PubMed ID: 24534345 [TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognosis of different subtypes of breast cancer]. Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the lymph node ratio in breast cancer subtypes. Liao GS; Chou YC; Golshan M; Hsu HM; Hong ZJ; Yu JC; Zhu JH Am J Surg; 2015 Oct; 210(4):749-54. PubMed ID: 26130268 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Sanpaolo P; Barbieri V; Genovesi D Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742 [TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes]. Zhang HM; Zhang BN; Xuan LX; Zhao P Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002 [TBL] [Abstract][Full Text] [Related]
9. Outcome in breast molecular subtypes according to nodal status and surgical procedures. Mazouni C; Rimareix F; Mathieu MC; Uzan C; Bourgier C; André F; Delaloge S; Garbay JR Am J Surg; 2013 Jun; 205(6):662-7. PubMed ID: 23312273 [TBL] [Abstract][Full Text] [Related]
10. [Clinical features and prognosis analysis of different breast cancer molecular subtypes]. Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463 [TBL] [Abstract][Full Text] [Related]
11. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of lymph node ratio in locally advanced breast cancer molecular subtypes. Demircioglu F; Demirci U; Kilic D; Ozkan S; Karahacioglu E Onkologie; 2013; 36(11):637-40. PubMed ID: 24192767 [TBL] [Abstract][Full Text] [Related]
13. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Matsubara N; Mukai H; Fujii S; Wada N Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081 [TBL] [Abstract][Full Text] [Related]
14. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187 [TBL] [Abstract][Full Text] [Related]
15. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420 [TBL] [Abstract][Full Text] [Related]
16. Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes. Kim J; Lee S; Bae S; Choi MY; Lee J; Jung SP; Kim S; Choe JH; Kim JH; Kim JS; Lee JE; Nam SJ; Yang JH Breast Cancer Res Treat; 2012 Jan; 131(2):527-40. PubMed ID: 22042364 [TBL] [Abstract][Full Text] [Related]
17. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899 [TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients]. Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207 [TBL] [Abstract][Full Text] [Related]
19. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer. Li J; Liu X; Tong Z Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058 [TBL] [Abstract][Full Text] [Related]
20. Luminal (Her2 negative) prognostic index and survival of breast cancer patients. Chen X; Cong Y; Pan L; Jiang Y; Meng Q; Sun L; Pang H; Zhao Y; Dong X; Cai L Cancer Epidemiol; 2014 Jun; 38(3):286-90. PubMed ID: 24725965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]